AbbVie Inc. is 277.6x more valuable than Palvella Therapeutics, Inc. by market capitalization ($399.47 B vs $1.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | PVLA | ABBV |
|---|---|---|
| Market cap | $1.44 B | $399.47 B |
| US-listed rank | #2360 | #28 |
| Revenue (latest FY) | $42.81M | $61.16B |
| Net income (latest FY) | -$41.72M | $4.23B |
| Net margin | -97.4% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 774 | 1,008 |
AbbVie Inc. is 277.6x more valuable than Palvella Therapeutics, Inc. by market capitalization ($399.47 B vs $1.44 B).
In their latest fiscal years, Palvella Therapeutics, Inc. reported $42.81M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Palvella Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.